abstract |
The present invention is directed to treating a new class of compounds, pharmaceutical compositions comprising said compounds, diseases or disorders associated with abnormal or deregulated kinase activity, in particular diseases or disorders involving abnormal activation of c-kit, PDGFRα and PDGFRβ kinases. A method of using said compound for prophylaxis. |